Nektar plans Phase 3 ZENITH-AD program after rezpegaldesleukin Phase 2b results

Reuters03-29

Nektar plans Phase 3 <a href="https://laohu8.com/S/ZENB.UK">ZENITH</a>-AD program after rezpegaldesleukin Phase 2b results

Nektar Therapeutics presented Phase 2b data at 2026 American Academy of Dermatology meeting for rezpegaldesleukin in moderate-to-severe atopic dermatitis.
REZOLVE-AD study enrolled 393 patients, showing statistically significant improvement in mean percent EASI improvement versus placebo across baseline vIGA-AD severity 3 or 4.
Trial also reported comparable EASI-75 and EASI-90 response rates during 16-week induction period across moderate and severe subgroups.
Separate late-breaking oral presentation highlighted Phase 2b REZOLVE-AA results in severe-to-very-severe alopecia areata at 36 weeks.
High-dose rezpegaldesleukin 24 µg/kg every two weeks cut mean SALT score 28.2% versus 11.2% for placebo; Nektar plans to start Phase 3 ZENITH-AD program in second quarter 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603281236PR_NEWS_USPR_____SF20824) on March 28, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623387895?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-29 00:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623387895","market":"fut","top_or_hot":-1,"title":"Nektar plans Phase 3 ZENITH-AD program after rezpegaldesleukin Phase 2b results","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nektar plans Phase 3 <a href=\"https://laohu8.com/S/ZENB.UK\">ZENITH</a>-AD program after rezpegaldesleukin Phase 2b results\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Nektar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> presented Phase 2b data at 2026 American Academy of Dermatology meeting for rezpegaldesleukin in moderate-to-severe atopic dermatitis.\n        </li>\n<li>\n          REZOLVE-AD study enrolled 393 patients, showing statistically significant improvement in mean percent EASI improvement versus placebo across baseline vIGA-AD severity 3 or 4.\n        </li>\n<li>\n          Trial also reported comparable EASI-75 and EASI-90 response rates during 16-week induction period across moderate and severe subgroups.\n        </li>\n<li>\n          Separate late-breaking oral presentation highlighted Phase 2b REZOLVE-AA results in severe-to-very-severe alopecia areata at 36 weeks.\n        </li>\n<li>\n          High-dose rezpegaldesleukin 24 µg/kg every two weeks cut mean SALT score 28.2% versus 11.2% for placebo; Nektar plans to start Phase 3 ZENITH-AD program in second quarter 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603281236PR_NEWS_USPR_____SF20824) on March 28, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nektar plans Phase 3 ZENITH-AD program after rezpegaldesleukin Phase 2b results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNektar plans Phase 3 ZENITH-AD program after rezpegaldesleukin Phase 2b results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-29 00:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nektar plans Phase 3 <a href=\"https://laohu8.com/S/ZENB.UK\">ZENITH</a>-AD program after rezpegaldesleukin Phase 2b results\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Nektar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> presented Phase 2b data at 2026 American Academy of Dermatology meeting for rezpegaldesleukin in moderate-to-severe atopic dermatitis.\n        </li>\n<li>\n          REZOLVE-AD study enrolled 393 patients, showing statistically significant improvement in mean percent EASI improvement versus placebo across baseline vIGA-AD severity 3 or 4.\n        </li>\n<li>\n          Trial also reported comparable EASI-75 and EASI-90 response rates during 16-week induction period across moderate and severe subgroups.\n        </li>\n<li>\n          Separate late-breaking oral presentation highlighted Phase 2b REZOLVE-AA results in severe-to-very-severe alopecia areata at 36 weeks.\n        </li>\n<li>\n          High-dose rezpegaldesleukin 24 µg/kg every two weeks cut mean SALT score 28.2% versus 11.2% for placebo; Nektar plans to start Phase 3 ZENITH-AD program in second quarter 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603281236PR_NEWS_USPR_____SF20824) on March 28, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NKTR","symbol_name":"内克塔治疗","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nNDL4MdTZz:1","article_id":"2623387895","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623387895","pubTimestamp":1774715783,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nektar Therapeutics presented Phase 2b data at 2026 American Academy of Dermatology meeting for rezpegaldesleukin in moderate-to-severe atopic dermatitis.REZOLVE-AD study enrolled 393 patients, showing statistically significant improvement in mean percent EASI improvement versus placebo across baseline vIGA-AD severity 3 or 4.Trial also reported comparable EASI-75 and EASI-90 response rates during 16-week induction period across moderate and severe subgroups.Separate late-breaking oral presentation highlighted Phase 2b REZOLVE-AA results in severe-to-very-severe alopecia areata at 36 weeks.High-dose rezpegaldesleukin 24 g/kg every two weeks cut mean SALT score 28.2% versus 11.2% for placebo; Nektar plans to start Phase 3 ZENITH-AD program in second quarter 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NKTR":"内克塔治疗","BK4007":"制药"},"translate_title":"Nektar计划在rezpegaldesleukin 2b期结果公布后进行3期ZENITH-AD计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NKTR":0.9},"content_text":"Nektar plans Phase 3 ZENITH-AD program after rezpegaldesleukin Phase 2b results\n    \n\n\n          Nektar Therapeutics presented Phase 2b data at 2026 American Academy of Dermatology meeting for rezpegaldesleukin in moderate-to-severe atopic dermatitis.\n        \n\n          REZOLVE-AD study enrolled 393 patients, showing statistically significant improvement in mean percent EASI improvement versus placebo across baseline vIGA-AD severity 3 or 4.\n        \n\n          Trial also reported comparable EASI-75 and EASI-90 response rates during 16-week induction period across moderate and severe subgroups.\n        \n\n          Separate late-breaking oral presentation highlighted Phase 2b REZOLVE-AA results in severe-to-very-severe alopecia areata at 36 weeks.\n        \n\n          High-dose rezpegaldesleukin 24 µg/kg every two weeks cut mean SALT score 28.2% versus 11.2% for placebo; Nektar plans to start Phase 3 ZENITH-AD program in second quarter 2026.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603281236PR_NEWS_USPR_____SF20824) on March 28, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623387895","isCrawlerRequest":true}